ITeos Therapeutics Inc (ITOS)
10.44
+0.09
(+0.87%)
USD |
NASDAQ |
Apr 19, 10:26
ITeos Therapeutics Cash from Operations (TTM): -103.76M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -103.76M |
| September 30, 2023 | -117.16M |
| June 30, 2023 | -112.97M |
| March 31, 2023 | -113.75M |
| December 31, 2022 | -111.19M |
| September 30, 2022 | -142.84M |
| June 30, 2022 | 491.86M |
| March 31, 2022 | 503.93M |
| December 31, 2021 | 513.14M |
| Date | Value |
|---|---|
| September 30, 2021 | 566.49M |
| June 30, 2021 | -48.74M |
| March 31, 2021 | -40.49M |
| December 31, 2020 | -25.18M |
| September 30, 2020 | -26.66M |
| June 30, 2020 | -21.97M |
| March 31, 2020 | -17.81M |
| December 31, 2019 | -23.14M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-142.84M
Minimum
Sep 2022
566.49M
Maximum
Sep 2021
68.81M
Average
-26.66M
Median
Sep 2020
Cash from Operations (TTM) Benchmarks
| Gilead Sciences Inc | 8.006B |
| Merck & Co Inc | 13.01B |
| Arcus Biosciences Inc | -306.00M |
| IGM Biosciences Inc | -192.23M |
| Forian Inc | 0.7288M |